(SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas

N/ACompletedNCT01949506

Medical College of Wisconsin9 enrolled

Overview

This is a prospective study to document the local control rates with SBRT specifically for pulmonary metastases from soft tissue sarcoma. This study will prospectively document acute and late toxicity, quality of life (QoL), tumor control, and survival.

A total of no more than 20 people are expected to participate in this study at the Medical College of Wisconsin/Froedtert Hospital. Patients will be followed for three years. The usual treatment for sarcomas that spread to the lungs is to remove the cancer with surgery. Patients who cannot have surgery or prefer not to have surgery, can receive radiation therapy. Standard radiation therapy involves several weeks of daily treatment sessions, although it is not as effective as surgery and may seriously damage normal surrounding lung tissue. Stereotactic body radiation therapy (SBRT) is a radiation treatment that gives fewer but higher doses of radiation than standard radiation. SBRT is used to treat metastases to the lung from many types of cancer but has not been used very often with patients who have metastatic disease to their lungs from sarcomas. The purpose of this study is to test the possibility of SBRT to the lung for metastatic disease to the lung. This information will be used to find out if there are factors that can predict recovery or outcome of patients with metastatic disease to the lung from sarcoma. SBRT will consist of 1 to 3 treatments per week for a total of 3 to 5 treatments to each tumor until therapy is complete. After SBRT is completed, follow-up exams will occur 4-6 weeks from the completion of radiation treatment, every 3 months in year 1 and every 6 months for 2 years.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Stage IV Adult Soft Tissue Sarcoma Sarcoma,Soft Tissue

Interventions

SBRTRADIATION

Stereotactic Body Radiation Therapy

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ≥18 years of age * Pathologic confirmation of primary soft tissue sarcoma with pathologic or radiographic evidence of pulmonary metastatic disease * No evidence of extra pulmonary progression of disease for 3 months prior to enrollment on study * 1-5 pulmonary lesions all ≤5 cm in size * Medically inoperable or declines surgery * Patients may have had previous treatment for pulmonary metastases Exclusion Criteria: * Patients who have uncontrolled extra-pulmonary disease * Pregnant women * Patients who have greater than 5 pulmonary lesions at the time of study enrollment * Patients who have disease progression outside the lungs within 3 months of enrollment on the study * Disease pathology other than sarcoma subtypes * Patients with a history of metastatic disease from a primary other than sarcoma

Locations (1)

Froedtert Hospital and Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Outcomes

Primary Outcomes

Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria.

This measure (number of adverse events of grade ≥ 3 by Common Terminology Criteria for Adverse Events (CTCAE) criteria) will provide information regarding the acute toxicity of SBRT for \< 5 pulmonary metastases from soft tissue sarcoma..The CTCAE criteria provide a standardized description of adverse events including guidelines for grading severity. The guidelines can be viewed at: https://ctep.cancer.gov/protocoldevelopment/electronic\_applications/ctc.htm.

Time frame: 6 weeks post SBRT

Secondary Outcomes

Number of Subjects Experiencing Locoregional Recurrences.

This measure (number of subjects experiencing locoregional recurrences) will provide information regarding locoregional control. Locoregional recurrence means any new or renewed tumor growth of any size observed by an imaging technology that is located at or adjacent to a prior treatment site.

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.